AbbVie Hit a New High After Earnings. There’s More Upside Left.
AbbVie (ABBV) rose to $295.56 after Q3 earnings beat estimates, with revenue up 10.3% and adjusted EPS at $3.82. The company raised full-year EPS guidance and increased its dividend. Skyrizi and Rinvoq drove growth, while Humira sales declined. Analysts set a price target of $291.77, with a bull case of $314.79.
How this was made
The 30-second read
Why it matters
Guidance raise and strong drug sales provide a fresh catalyst for the stock, though valuation concerns persist.
Market read
The earnings beat and guidance raise are primary drivers for AbbVie's recent rally and set expectations for near‑term price action.
What to watch
Intangible amortization and upcoming patent expiries could dampen cash flow despite guidance lift.
Background
AbbVie reported Q3 results with revenue up 10.3% and EPS beat, raising full‑year EPS guidance and dividend.
Ticker impact
Q3 earnings beat estimates and full-year EPS guidance raised to $13.95‑$13.99, with dividend increase, driving a 33% YTD stock rally.
likely modest upside as market prices in higher earnings outlook
Guidance raise and dividend hike are fresh, material data for a large‑cap pharma; traders can position for incremental gains.
Market effects
Strengthens the immunology and neuroscience segments, supporting peers like JNJ and BMY.
U.S. pharma sector may see modest rally in the afternoon session.
Highlights continued demand for biologics, relevant for global biotech investors.
Counterpoint
Valuation remains high (P/E 122) and Humira erosion could pressure earnings if new drugs underperform.
Key entities
- companyAbbVie
Pharmaceutical firm reporting earnings and guidance lift.
